ATE200030T1 - Pegylationsverfahren - Google Patents

Pegylationsverfahren

Info

Publication number
ATE200030T1
ATE200030T1 AT98901405T AT98901405T ATE200030T1 AT E200030 T1 ATE200030 T1 AT E200030T1 AT 98901405 T AT98901405 T AT 98901405T AT 98901405 T AT98901405 T AT 98901405T AT E200030 T1 ATE200030 T1 AT E200030T1
Authority
AT
Austria
Prior art keywords
substrate
pegylation
peg
attachment
reaction
Prior art date
Application number
AT98901405T
Other languages
English (en)
Inventor
Gillian Elizabeth Francis
Derek Fisher
Farooq Malik
Original Assignee
Polymasc Pharmaceuticals Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9701804.8A external-priority patent/GB9701804D0/en
Priority claimed from GBGB9701800.6A external-priority patent/GB9701800D0/en
Priority claimed from GBGB9704653.6A external-priority patent/GB9704653D0/en
Priority claimed from GBGB9708055.0A external-priority patent/GB9708055D0/en
Application filed by Polymasc Pharmaceuticals Plc filed Critical Polymasc Pharmaceuticals Plc
Application granted granted Critical
Publication of ATE200030T1 publication Critical patent/ATE200030T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • External Artificial Organs (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98901405T 1997-01-29 1998-01-28 Pegylationsverfahren ATE200030T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9701804.8A GB9701804D0 (en) 1997-01-29 1997-01-29 Pegylation process
GBGB9701800.6A GB9701800D0 (en) 1997-01-29 1997-01-29 Pegylation process
GBGB9704653.6A GB9704653D0 (en) 1997-03-06 1997-03-06 Pegylation process
GBGB9708055.0A GB9708055D0 (en) 1997-04-22 1997-04-22 Pegylation process
PCT/GB1998/000253 WO1998032466A1 (en) 1997-01-29 1998-01-28 Pegylation process

Publications (1)

Publication Number Publication Date
ATE200030T1 true ATE200030T1 (de) 2001-04-15

Family

ID=27451595

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98901405T ATE200030T1 (de) 1997-01-29 1998-01-28 Pegylationsverfahren

Country Status (6)

Country Link
EP (1) EP0921817B1 (de)
JP (1) JP2001508783A (de)
AT (1) ATE200030T1 (de)
AU (1) AU5773798A (de)
DE (1) DE69800640T2 (de)
WO (1) WO1998032466A1 (de)

Families Citing this family (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US8007784B1 (en) 1996-06-27 2011-08-30 Albany Medical College Antigenic modulation of cells
US6548263B1 (en) 1997-05-29 2003-04-15 Cellomics, Inc. Miniaturized cell array methods and apparatus for cell-based screening
WO1999000145A1 (en) * 1997-06-26 1999-01-07 Albany Medical College Antigenic modulation of viral particules
WO1999017120A1 (en) * 1997-09-26 1999-04-08 Becton, Dickinson And Company Preparing conjugates using polyethylene glycol linkers
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AU2605099A (en) * 1998-02-25 1999-09-15 Micrologix Biotech, Inc. Indolicidin and cationic peptides conjugated with polymers
ES2224649T3 (es) * 1998-04-28 2005-03-01 Applied Research Systems Ars Holding N.V. Conjugados de poliol-ifn-beta.
AU4253799A (en) * 1998-06-12 2000-01-05 Micrologix Biotech, Inc. Cancer therapy with cationic peptides
EP2599503B1 (de) 1998-10-16 2017-05-17 Biogen MA Inc. Polymerkonjugate von Interferon-Beta-1A und Verwendungen dafür
DK1121382T3 (da) 1998-10-16 2006-11-13 Biogen Idec Inc Interferon-beta-fusionsproteiner og deres anvendelser
EP1144452B1 (de) * 1998-11-03 2006-01-11 Centocor, Inc. Modifizierte antikörper und antikörper-fragmente mit verlängerter aktivitätsdauer
JP2002531089A (ja) * 1998-11-30 2002-09-24 イーライ・リリー・アンド・カンパニー 赤血球産生性化合物
US6958212B1 (en) 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
WO2000044808A1 (en) 1999-02-01 2000-08-03 Hubbell Jeffrey A Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
CA2363779A1 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
HUP0203751A3 (en) 2000-01-10 2005-01-28 Maxygen Holdings Ltd Redwood C G-csf conjugates
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
AU2001261024A1 (en) 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7291673B2 (en) 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
AU2001275226B2 (en) * 2000-06-02 2007-06-28 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
AU2001268228A1 (en) 2000-06-08 2001-12-17 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
EP1294949A4 (de) 2000-06-15 2004-08-25 Human Genome Sciences Inc Menschlicher tumornekrosefaktor delta und epsilon
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) * 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
EP2267015A3 (de) 2000-08-18 2011-04-20 Human Genome Sciences, Inc. Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
EP1333036B1 (de) * 2000-10-16 2009-01-21 Chugai Seiyaku Kabushiki Kaisha Peg-modifiziertes erythropoietin
EP1355965B1 (de) 2000-10-19 2012-09-19 Ecole Polytechnique Fédérale de Lausanne (EPFL) Verfahren zur herstellung von blockcopolymeren für multifunktionelle selbstorganisierende systeme
EP1345628B1 (de) 2000-12-20 2011-04-13 F. Hoffmann-La Roche AG Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
JP4656814B2 (ja) * 2000-12-20 2011-03-23 エフ．ホフマン−ラ ロシュ アーゲー エリスロポエチンコンジュゲート
DE10102878A1 (de) 2001-01-23 2002-08-01 Haemosys Gmbh Oligo- oder Polyalkylengekoppelte Thrombininhibitoren
MXPA03007619A (es) 2001-02-27 2003-12-04 Maxygen Aps Nuevas moleculas similares a interferon beta.
PL371800A1 (en) * 2001-03-22 2005-06-27 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
US7235638B2 (en) 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
AR033903A1 (es) 2001-05-21 2004-01-07 Inhale Therapeutic Syst Una composicion de insulina modificada quimicamente para la administracion pulmonar
MXPA03010747A (es) 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
ES2320979T3 (es) 2001-09-24 2009-06-01 Imperial Innovations Limited Pyy-36 para la reduccion o prevencion de la obesidad.
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
EP2277910A1 (de) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin Fusionsproteine
CA2472882A1 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
SK3102004A3 (sk) 2002-01-18 2005-01-03 Biogen Idec MA Inc. Polyalkylénglykol s časťou na konjugáciu biologicky aktívnej zlúčeniny
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
WO2003082926A2 (en) * 2002-03-26 2003-10-09 Biosynexus Incorporated Antimicrobial polymer conjugates
CN101942019A (zh) 2002-04-30 2011-01-12 拜耳医药保健有限公司 凝血因子VII或VIIa多肽变体
KR101186140B1 (ko) * 2002-06-21 2012-09-27 노보 노르디스크 헬스 케어 악티엔게젤샤프트 페길화된 인자 ｖｉｉ 글리코형태
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
EP1681303B1 (de) * 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylierte Polypeptide, besonders HASyliertes Erythropoietin
AU2003273413A1 (en) 2002-10-08 2004-05-04 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
JP4847856B2 (ja) 2003-03-20 2011-12-28 バイエル ヘルスケア エルエルシー ＦＶＩＩおよびＦＶＩＩａの変種
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
CN1774281B (zh) * 2003-04-15 2010-10-13 奥珀百思控股公司 包含蛋白质和/或多肽以及胶体颗粒的药物组合物
EP1644504B8 (de) 2003-06-19 2010-06-02 Bayer HealthCare LLC Varianten der faktor-vii- oder -viia-gla-domäne
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EP1673387B1 (de) 2003-10-10 2010-09-15 Novo Nordisk A/S Il-21-derivate
EP2633866A3 (de) 2003-10-17 2013-12-18 Novo Nordisk A/S Kombinationstherapie
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
SI1696947T1 (sl) 2003-12-19 2014-05-30 F. Hoffmann-La Roche Ag Uporaba eritropoetina pri zdravljenju motenj porazdelitve železa pri kroničnih vnetnih črevesnih boleznih
EP2289567A3 (de) 2003-12-22 2011-06-22 Regentis Biomaterials Ltd. Matrix aus natürlich vorkomendem vernetztem Protein
US7842667B2 (en) 2003-12-22 2010-11-30 Regentis Biomaterials Ltd. Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
NZ548255A (en) 2004-02-02 2010-10-29 Ambrx Inc Modified human interferon polypeptides and their uses
EP1729795B1 (de) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albuminfusionsproteine
KR20070034512A (ko) 2004-06-18 2007-03-28 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
ATE491475T1 (de) * 2004-07-16 2011-01-15 Nektar Therapeutics Konjugate enthaltend gm-csf und ein polymer
AU2009212311B8 (en) 2004-07-21 2013-05-30 Ambrx, Inc. Modified leptin polypeptides and their uses
EP1771573A4 (de) 2004-07-21 2009-02-18 Ambrx Inc Nichtnatürliche kodierte aminosäuren verwendende biosynthetische polypeptide
WO2006015512A1 (en) * 2004-08-11 2006-02-16 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. A modified arginine deiminase
EP2586456B1 (de) 2004-10-29 2016-01-20 ratiopharm GmbH Umformung und GlycoPEGylierung des Fibroblastenwachstumsfaktors (FGF)
US7597907B2 (en) 2004-11-05 2009-10-06 Trustees Of The University Of Pennsylvania Antioxidant polymer nanocarriers for use in preventing oxidative injury
WO2006073846A2 (en) 2004-12-22 2006-07-13 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
NZ555386A (en) 2004-12-22 2011-01-28 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
ATE541934T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
JP2008525473A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 修飾されたヒト成長ホルモン
JP4951527B2 (ja) 2005-01-10 2012-06-13 バイオジェネリックス アーゲー 糖ｐｅｇ化顆粒球コロニー刺激因子
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US9505867B2 (en) 2005-05-31 2016-11-29 Ecole Polytechmique Fédérale De Lausanne Triblock copolymers for cytoplasmic delivery of gene-based drugs
MX2007015058A (es) 2005-06-03 2008-01-28 Ambrx Inc Moleculas de interferon humano mejoradas y sus usos.
EP1893632B1 (de) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selektive reduktion und derivatisierung manipulierter faktor vii proteine mit mindestens einem nichtnativen zystein
KR101285904B1 (ko) 2005-08-18 2013-07-15 암브룩스, 인코포레이티드 ｔＲＮＡ 조성물 및 이의 용도
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007047997A2 (en) 2005-10-19 2007-04-26 Smartcells, Inc. Methods for reducing the mitogenicity of lectin compositions
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
CN101454461A (zh) 2005-11-16 2009-06-10 Ambrx公司 包括非天然氨基酸的方法和组合物
WO2007087673A1 (en) 2006-02-01 2007-08-09 Arana Therapeutics Limited Domain antibody construct
CA2800389A1 (en) 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compounds
RU2008145084A (ru) 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
EP2054437A2 (de) 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin-fusionsproteine
AU2007292892B9 (en) 2006-09-08 2013-02-28 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
AU2007292893B2 (en) 2006-09-08 2012-03-01 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
EP2698157B1 (de) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Verfahren zur Behandlung von Fettsäure-Synthese-Hemmern
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス ポリペプチドコンジュゲートの精製方法
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CN101557830B (zh) 2006-12-15 2016-06-08 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
EP2068909B1 (de) 2007-03-30 2012-04-25 Ambrx, Inc. Modifizierte fgf-21 polypeptide und ihre verwendung
WO2008120653A1 (ja) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. インドールジオン誘導体
AU2008237411B2 (en) 2007-04-03 2013-10-03 Ratiopharm Gmbh Methods of treatment using glycopegylated G-CSF
CN101675071B (zh) 2007-05-02 2014-06-18 Ambrx公司 经修饰干扰素β多肽和其用途
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US7927629B2 (en) 2007-10-27 2011-04-19 The Trustees Of The University Of Pennsylvania Method and compositions for polymer nanocarriers containing therapeutic molecules
US8568786B2 (en) 2007-10-27 2013-10-29 The Trustees Of The Universtiy Of Pennsylvania Method and compositions for polymer nanocarriers containing therapeutic molecules
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
WO2009108806A1 (en) 2008-02-27 2009-09-03 Novo Nordisk A/S Conjugated factor viii molecules
EP2260102A1 (de) 2008-03-25 2010-12-15 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tumorbehandlung mittels herunterregelung von frizzled-4 und/oder frizzled-1
CN106928339A (zh) 2008-07-23 2017-07-07 Ambrx 公司 经修饰的牛g‑csf多肽和其用途
CA2737026C (en) 2008-09-26 2019-12-24 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
PT2337846T (pt) 2008-09-26 2018-04-05 Ambrx Inc Vacinas e microrganismos dependentes da replicação de aminoácidos não naturais
JP5814793B2 (ja) 2008-11-25 2015-11-17 エコール ポリテクニク フェデラル ド ローザンヌ（エーペーエフエル） ブロックコポリマーおよびその使用
AU2010208305A1 (en) 2009-01-28 2011-09-08 Smartcells, Inc. Synthetic conjugates and uses thereof
EP2405920A1 (de) 2009-03-06 2012-01-18 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Neue therapie gegen angstzustände
AU2010226243A1 (en) 2009-03-20 2011-09-22 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
US8580732B2 (en) 2009-04-07 2013-11-12 Duke University Peptide therapy for hyperglycemia
EP2241323A1 (de) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W und Hirnkrebs
EP2292266A1 (de) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Behandlung von Krebs durch Modulation von Copine III
WO2011036118A1 (en) 2009-09-22 2011-03-31 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mex-3
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
AU2010339794B2 (en) 2009-12-17 2016-09-22 Children's Medical Center Corporation Saposin-A derived peptides and uses thereof
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
EP2516455A4 (de) 2009-12-21 2013-05-22 Ambrx Inc Modifizierte schweine-somatotropin-polypeptide und deren verwendungen
JP6148013B2 (ja) 2010-03-05 2017-06-14 リグショスピタレト 補体活性化のキメラ抑制分子
EP2542578A1 (de) 2010-03-05 2013-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Smoc1, tenascin-c und hirnkrebs
EP2561076A1 (de) 2010-04-19 2013-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulation von xrn1
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
WO2011154485A1 (en) 2010-06-10 2011-12-15 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mammalian sterile 20-like kinase 3
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EP2605789B1 (de) 2010-08-17 2019-06-05 Ambrx, Inc. Modifizierte relaxinpolypeptide und ihre verwendungen
WO2012032143A1 (en) 2010-09-10 2012-03-15 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Phosphorylated twist1 and metastasis
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
EP2640738A1 (de) 2010-11-15 2013-09-25 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Antimykotische wirkstoffe
EP2474612A1 (de) 2011-01-05 2012-07-11 University College Dublin, National University of Ireland Dublin Affinitätstrennungsmittel und ihre Verwendungen zur Trennung, Reinigung und Konzentration von Zielmolekülen
US9181553B2 (en) 2011-06-06 2015-11-10 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Method of treatment of breast cancers over-expressing the SHP2 signature genes
WO2013004607A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
WO2013068431A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
US20140294732A1 (en) 2011-11-08 2014-10-02 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Early diagnostic of neurodegenerative diseases
EP4306123A3 (de) 2011-12-22 2024-04-17 Children's Medical Center Corporation Aus saposin-a gewonnene peptide und verwendungen davon
WO2013102825A1 (en) 2012-01-02 2013-07-11 Novartis Ag Cdcp1 and breast cancer
US9474810B2 (en) * 2012-03-02 2016-10-25 General Electric Company Superparamagnetic nanoparticles with PEG substituted α-hydroxy phosphonate shells
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
EP2831112A1 (de) 2012-03-29 2015-02-04 Friedrich Miescher Institute for Biomedical Research Hemmung von interleukin 8 und/oder dessen rezeptor cxcrl bei der behandlung von brustkrebs mit her2/her3-überexpression
AP2014008049A0 (en) 2012-04-16 2014-11-30 Cantab Biopharmaceuticals Patents Ltd Optimised subcuraneous therapeutic agents
ES2718478T3 (es) 2012-06-08 2019-07-02 Sutro Biopharma Inc Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
EP2866831A1 (de) 2012-06-29 2015-05-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Behandlung von krankheiten durch modulation einer spezifischen isoform von mkl1
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
AU2013308494B2 (en) 2012-08-31 2018-03-01 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
US10711106B2 (en) 2013-07-25 2020-07-14 The University Of Chicago High aspect ratio nanofibril materials
WO2015019286A1 (en) 2013-08-07 2015-02-12 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment friedreich's ataxia
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
CN104007079B (zh) * 2014-04-18 2016-06-29 深圳赛保尔生物药业有限公司 重组人促红素聚乙二醇化反应液的光谱检测法及应用
US20170137824A1 (en) 2014-06-13 2017-05-18 Indranil BANERJEE New treatment against influenza virus
US10308935B2 (en) 2014-06-23 2019-06-04 Friedrich Miescher Institute For Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
WO2016046768A1 (en) 2014-09-24 2016-03-31 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
KR102854572B1 (ko) 2014-10-24 2025-09-02 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
KR20180031775A (ko) 2015-08-12 2018-03-28 셀 머신스, 인크. 긴 반감기 응집 복합체와 관련된 방법 및 조성물
EP3368566A1 (de) 2015-10-28 2018-09-05 Friedrich Miescher Institute for Biomedical Research Tenascin-w und gallengangkrebs
BR112019016139A2 (pt) 2017-02-08 2020-04-07 Bristol-Myers Squibb Company polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo
WO2019030692A1 (en) 2017-08-10 2019-02-14 Friedrich Miescher Institute For Biomedical Research HDAC6 AND AGGREGATION OF PROTEINS
WO2020056066A1 (en) 2018-09-11 2020-03-19 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
AU2019361206A1 (en) 2018-10-19 2021-06-03 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
WO2020168017A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
CN120682337A (zh) 2020-03-11 2025-09-23 北京泰德制药股份有限公司 白介素-2多肽偶联物及其使用方法
TW202227449A (zh) 2020-08-20 2022-07-16 美商Ａｍｂｒｘ 公司 抗體－ｔｌｒ促效劑偶聯物、其方法及用途
MX2023011480A (es) 2021-04-03 2023-12-06 Ambrx Inc Conjugados anticuerpo anti-her2-fármaco y usos de estos.
CN114230739B (zh) * 2021-12-14 2023-08-11 西安交通大学 一种线性-非线性嵌段聚合物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4912599B1 (de) * 1970-07-02 1974-03-26
WO1985003934A1 (fr) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
GB8824592D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Purification process
GB8824593D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
JP2997004B2 (ja) * 1989-05-26 2000-01-11 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
NZ244778A (en) * 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
WO1994004193A1 (en) * 1992-08-21 1994-03-03 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
WO1994023726A1 (en) * 1993-04-22 1994-10-27 Mallinckrodt Medical, Inc. Calmodulin blocking agent adducts useful as anti-platelet agents
GB9317618D0 (en) * 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
WO1995033490A1 (en) * 1994-06-02 1995-12-14 Enzon, Inc. Method of solubilizing substantially water insoluble materials
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods

Also Published As

Publication number Publication date
JP2001508783A (ja) 2001-07-03
EP0921817A1 (de) 1999-06-16
DE69800640D1 (en) 2001-05-03
WO1998032466A1 (en) 1998-07-30
EP0921817B1 (de) 2001-03-28
DE69800640T2 (de) 2001-07-05
AU5773798A (en) 1998-08-18

Similar Documents

Publication Publication Date Title
ATE200030T1 (de) Pegylationsverfahren
ATE263157T1 (de) Nematizide trifluorbutene
EP0528858A4 (en) Inhibitors of dipeptidyl-aminopeptidase type iv
WO1998011900A3 (en) Compositions containing cobalamin and amino acids
DE3378052D1 (en) Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
BR9810953A (pt) "processo para produzir policarbonatos ramificados"
TW289020B (de)
DK0912176T3 (da) Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression
LU91204I2 (fr) Pegvisomant, facultativement sous forme d'une variante de pégylation
EP1391536A3 (de) Zusammensetzung und Verfahren zur Plattierung von Silber auf ein metallisches Substrat
NO20020348D0 (no) Peptid acceptor ligeringsmetoder
WO1999064047A8 (en) Novel antiviral compounds
WO1994024187A3 (en) Organosilicon-containing materials useful for biomedical devices
AU7998291A (en) Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
GB0011203D0 (en) Chemical compounds
ITRM940018A0 (it) Procedimento per la preparazione di polimeri ammina-aldeide contenentigruppi solfo, polimeri ottenuti secondo questo procedimento e loro impiego. (caso 154-0238)
NZ501751A (en) Process for covalently coupling organic compounds using a diboron derivative and a Group VIII metal catalyst
CY1106978T1 (el) Ενζυμα φωσφοδιεστερασης
ES2109418T3 (es) Procedimiento para la preparacion de polimeros a base de monoxido de carbono y olefinas.
DE3878301D1 (de) Desinfizierende polymerbeschichtungen fuer harte oberflaechen.
DE3765765D1 (de) Polymere als beizmittel fuer saure farbstoffe.
TR200002755T2 (tr) Aracı hazırlamak için süreç.
DE59502219D1 (de) Verfahren zur Herstellung von 2-Amino-4,6-dichloro-pyrimidin
CY1106051T1 (el) ΔΙΑΔΙΚΑΣΙΑ ΓΙΑ ΤΗΝ ΠΑΡΑΓΩΓΗ Ν-ΠΡΟΣΤΑΤΕΥΜΕΝΩΝ ΑΖΕΤΙΔΙΝΟ-2-ΚΑΡΒΟΞΥΛΙΚΩΝ ΟΞΕΩΝ (AzeOHs)
AU6290398A (en) Inclusion complexes in aqueous solution

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties